ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0506

Patient and Physician Global Assessment of Psoriatic Arthritis Disease Activity: High Concordance in an ArLAR Multinational Study

Nelly Ziade1, Noura Abbas2, Lina El Kibbi3, Avin Maroof4, Bassel Elzorkany5, Nizar Ani6, ASAL ADNAN7, NABAA IHSAN JAWAD AWADH7, Faiq Gorial8, Nada Alchama9, Chafika Haouichat10, Fatima Alnaimat11, Suad Hannawi12, Saed Atawnah13, HUSSEIN HALABI14, Manal Al-Mashaleh15, Laila Aljazwi16, Ahmed Abogamal17, laila Ayoub18, Elyes Bouajina19, Rachid Bahiri20, Sahar Saad21, Maha Sabkar21, Krystel Aouad22, Laure Gossec23 and Ihsane Hmamouchi24, 1Saint-Joseph University, Beirut, Lebanon, 2Saint Joseph University Beirut, Beirut, Lebanon, 3Specialized Medical Center, Riyadh, Saudi Arabia, 4Kurdistan University Hawler, Erbil, Iraq, 5Private (BZRC), Cairo, Egypt, 6Baghdad College of Medicine, Baghdad, Iraq, 7Baghdad Teaching Hospital, Baghdad, Iraq, 8University of Baghdad, Baghdad, Iraq, 9Ebn Al Nafiss Hospital, Damascus, Syria, 10Faculty of Medicine El Mahdi Si Ahmed, Blida, Algeria, 11University of Jordan, Amman, Jordan, 12Kuwait Hospital, Department of Rheumatology, Dubai, United Arab Emirates, 13Al ahli hospital, Hebron, Palestine, Hebron, Palestinian Territories, 14King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia, 15Royal Medical Services, Amman, Jordan, 16Tripoli, Tripoli, Libya, 17Saudi German Hospital Dubai, Dubai, United Arab Emirates, 18University of Tripoli, Tripoli, Libya, 19Farhat Hached Hospital of Sousse, Sousse, Tunisia, 20Department of Rheumatology, El Ayachi Hospital Medical University, Sale, Morocco, 21King Hamad University Hospital, Bahrain, Bahrain, 22Saint George Hospital University Medical Center, Beirut, Lebanon, 23Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, 24Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Morocco

Meeting: ACR Convergence 2023

Keywords: Education, Patient reported outcomes, Psoriatic arthritis, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: In patients with psoriatic arthritis (PsA), discordance between physicians and patients when assessing disease activity has been described as frequent, mainly in European and North American studies. This discordance may negatively impact treatment adherence and shared decision-making processes. Culture and beliefs influence patients’ perceptions of health.

The purpose of this study was to evaluate the concordance between patient- (PGA) and physician-global assessment (PhGA) of PsA disease activity and its association with demographic and disease characteristics in a multinational group of patients from Arab countries.

Methods: This multicentric multinational cross-sectional study was conducted in thirteen Arab countries by the Arab League of Associations of Rheumatology (ArLAR) research group (ARCH). During a single routine visit, patients and physicians rated PsA disease activity on a numeric scale from 0 (no activity) to 10 (worse activity). In addition, demographic and disease data were collected, as well as PGA and PhGA for psoriasis (PsO) activity, Health Assessment Questionnaire (HAQ), Fibromyalgia Rapid Screening Tool (FiRST), Patient Health Questionnaire (PHQ4) and Disease Activity in Psoriatic Arthritis (DAPSA). First, the correlation between PGA and PhGA for PsA and PsO disease activity was assessed statistically using the Spearman correlation coefficient and graphically using the Bland and Altman method. Second, concordance between the PGA and PhGA PsA activity (defined as a difference between -2 and 2) was calculated and correlated with demographic and disease factors using multivariable binary logistic regression.

Results: The study included 554 patients from thirteen countries: mean age 45 years (SD 13), 57% females, median disease duration four years (IQR 2-9); 89.2% had skin PsO, and 43.5% had nail PsO. The disease was active overall: mean DAPSA was 19.3 (SD 16.1), HAQ 1.1 (SD 0.8), and PHQ4 3.3 (SD 2.9). The screening test for widespread pain was positive in 18.4% of patients (Table 1). The mean PGA for PsA activity was 4.7 (SD 2.5) versus a PhGA of 3.9 (SD 2.4). Similarly, PGA for psoriasis activity was 4.0 (SD 2.8), and PhGA was 3.1 (SD 2.6). The correlation between PGA and PhGA was strong for PsA activity (r= 0.738) (with good agreement on Bland and Altman (Figure 1)) and moderate for psoriasis activity (r=0.613). Among 554 patients’ measurements, 358 (84.2%) were in concordance with the physician’s global assessment (Figure 2). In the multivariable analysis, concordance was independently associated with a high CRP (OR 2.32 [95%CI 1.33; 4.02] and DAPSA category (better concordance in patients in remission (OR 1.02 (95%CI 1.01; 1.03]).

Conclusion: In this unselected sample of patients from Arab countries, there was a strong concordance between PGA and PhGA of PsA activity. This raises questions about patient expectations and pain perceptions in Arab countries. Concordance was stronger for PsA than PsO, indicating that rheumatologists may be more comfortable assessing joints than skin. The patient’s evaluation of disease activity needs to be taken into account when considering the disease management plan, especially in patients who are not in remission.

Supporting image 1

Table 1. Patients’ and disease’s characteristics.

Supporting image 2

Figure 1. Agreement between PGA (Patient) and PhGA (Physician Global Assessment) of PsA activity using the Bland and Altman plot. Each dot is the difference between PGA and PhGA for a specific patient.

Supporting image 3

Figure 2. Concordance between PGA and PhGA of PsA activity, defined by a difference (PGA – PhGA) comprised between _2 and +2 (total available = 538 pairs)


Disclosures: N. Ziade: Abbvie, 6, Boehringer-Ingelheim, 6, Eli Lilly, 6, Janssen, 6, Newbridge, 6, Novartis, 6, Pfizer, 6, Pierre Fabre, 6, Roche, 6, sanofi, 6; N. Abbas: None; L. El Kibbi: None; A. Maroof: None; B. Elzorkany: None; N. Ani: None; A. ADNAN: None; N. AWADH: None; F. Gorial: None; N. Alchama: None; C. Haouichat: None; F. Alnaimat: None; S. Hannawi: GSK, 2, 6; S. Atawnah: None; H. HALABI: None; M. Al-Mashaleh: None; L. Aljazwi: None; A. Abogamal: None; l. Ayoub: None; E. Bouajina: None; R. Bahiri: None; S. Saad: None; M. Sabkar: None; K. Aouad: None; L. Gossec: AbbVie, 2, 12, Personal fees, Amgen, 2, Biogen, 5, BMS, 12, Personal fees, Celltrion, 12, Personal fees, Eli Lilly, 5, 12, Personal fees, Galapagos, 12, Personal fees, Janssen, 12, Personal fees, MSD, 12, Personal fees, Novartis, 5, 12, Personal fees, Pfizer, 12, Personal fees, Sandoz, 5, 12, Personal fees, UCB Pharma, 5, 12, Personal fees; I. Hmamouchi: None.

To cite this abstract in AMA style:

Ziade N, Abbas N, El Kibbi L, Maroof A, Elzorkany B, Ani N, ADNAN A, AWADH N, Gorial F, Alchama N, Haouichat C, Alnaimat F, Hannawi S, Atawnah S, HALABI H, Al-Mashaleh M, Aljazwi L, Abogamal A, Ayoub l, Bouajina E, Bahiri R, Saad S, Sabkar M, Aouad K, Gossec L, Hmamouchi I. Patient and Physician Global Assessment of Psoriatic Arthritis Disease Activity: High Concordance in an ArLAR Multinational Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/patient-and-physician-global-assessment-of-psoriatic-arthritis-disease-activity-high-concordance-in-an-arlar-multinational-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-and-physician-global-assessment-of-psoriatic-arthritis-disease-activity-high-concordance-in-an-arlar-multinational-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology